BullFrog AI Strengthens Capabilities of its AI Platform Through Expansion of Licensing Agreement With Johns Hopkins Applied Physics Laboratory

5 June 2023 -- Marlyland, US -- BullFrog AI Holdings, Inc., a digital technology company using machine learning (ML) to usher in a new era of precision medicine, today announced the expansion of its worldwide license agreement with the Johns Hopkins Applied Physics Laboratory (APL), in Laurel, Maryland, for use of patented technology powering the Company’s bfLEAP platform, an AI-driven platform for analysing drug development data to potentially make life-saving therapies and treatments available to patients more quickly.

“We are committed to firmly establishing BullFrog AI as the undisputed leader in artificial intelligence-driven drug development,” said Vin Singh, founder and CEO of BullFrog AI. "Our expanded license with APL is a testament to our relentless pursuit of innovation, enabling us to harness the full potential of AI in accelerating the development of life-saving therapies. This breakthrough technology not only has the potential to disrupt the industry, but also transform countless lives across the globe."

The patented technology from APL powering bfLEAP includes analytical models that enable the analysis and interpretation of large, complex and diverse datasets that may be incomplete and comprise both numerical and categorical data and provide explainable results. The innovative technology, which enables the detection of anomalies, patterns and relationships, has been shown to perform better than well-known algorithms in benchmarking tests.

The latest APL license improvements enable bfLEAP capabilities to be much more robust, both from a software perspective and mathematically. Additionally, the introduction of multivariate diffuse indexing, a new algorithm for analysis of mixed categorical/numerical data that supports both link inference and probabilistic modelling, allows probabilistic models to work with mixed data without any additional transformation.

Furthermore, the creation of a new repository that now houses all of the graph algorithms has led to a more organised structure with three equivalent-sized repositories containing around 80 runnable analytics each. This update brings numerous robustness and usability improvements to the platform.

BullFrog AI is deploying bfLEAP for use at several critical stages of therapeutics development with the intention of streamlining data analytics, decreasing the overall development costs by decreasing failure rates for new therapeutics and impacting the lives of countless patients that may otherwise not receive the therapies they need.

About BullFrog AI
BullFrog AI is a digital technology company using ML to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP artificial intelligence (AI) platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may seek to receive the therapies they need. For more information, visit BullFrog AI at www.bullfrogai.com.